Monthly
US$200
Billed every month
Doxofylline Injection(多索茶碱注射液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 2 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders39View records ↓
Under-review filings5View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers62View records ↓
API companies with A status23View records ↓
Chemical-drug catalogue
Loaded records: 39 holders; 10 in the quality-and-efficacy consistency-evaluation category, and 29 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 河南普瑞药业有限公司 | 河南普瑞药业有限公司 | 国药准字H20265518 | 2026/08/04 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 通化谷红制药有限公司 | 通化谷红制药有限公司 | 国药准字H20269032 | 2026/02/11 | 20ml:0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 云南药科院生物医药股份有限公司 | 楚雄和创药业有限责任公司 | 国药准字H20255789 | 2025/10/28 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 东阳祥昇医药科技有限公司 | 浙江北生药业汉生制药有限公司 | 国药准字H20258160 | 2025/08/13 | 20ml：0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖北午时医药研究院有限公司 | 湖北午时药业股份有限公司 | 国药准字H20253668 | 2025/03/18 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江昂利康制药股份有限公司 | 浙江创新生物有限公司 | 国药准字H20253360 | 2025/02/08 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东益健药业有限公司 | 山东益健药业有限公司 | 国药准字H20253302 | 2025/01/24 | 10ml:0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏明圣康源药业有限公司 | 江苏九旭药业有限公司 | 国药准字H20244712 | 2024/08/20 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 陕西博森生物制药股份集团有限公司 | 陕西博森生物制药股份集团有限公司 | 国药准字H20244561 | 2024/07/30 | 10ml：0.1g | Not stated by source | CDE |
| 陕西博森生物制药股份集团有限公司 | 陕西博森生物制药股份集团有限公司 | 国药准字H20244562 | 2024/07/30 | 20ml：0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖北美林药业有限公司 | 湖北美林药业有限公司 | 国药准字H20244081 | 2024/06/18 | 20ml:0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖北美林药业有限公司 | 湖北美林药业有限公司 | 国药准字H20244080 | 2024/06/18 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东鲁抗医药集团赛特有限责任公司 | 山东鲁抗医药集团赛特有限责任公司 | 国药准字H20243777 | 2024/05/21 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 赤峰万泽药业股份有限公司 | 河北天成药业股份有限公司 | 国药准字H20243638 | 2024/04/30 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 河北凯威恒诚制药有限公司 | 河北凯威制药有限责任公司 | 国药准字H20243618 | 2024/04/24 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 国药集团国瑞药业有限公司 | 国药集团国瑞药业有限公司 | 国药准字H20243015 | 2024/01/09 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 西洲医药科技（浙江）有限公司 | 浙江北生药业汉生制药有限公司 | 国药准字H20234452 | 2023/10/30 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川宏明博思药业有限公司 | 成都百裕制药股份有限公司 | 国药准字H20183230 | 2023/07/17 | 10ml:0.1g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 山东齐都药业有限公司 | 山东齐都药业有限公司 | 国药准字H20233433 | 2023/04/11 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 吉林振澳制药有限公司 | 吉林振澳制药有限公司 | 国药准字H20233215 | 2023/02/21 | 10ml:0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 合肥康诺生物制药有限公司 | 开封康诺药业有限公司 | 国药准字H20233192 | 2023/02/14 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 通化谷红制药有限公司 | 通化谷红制药有限公司 | 国药准字H20223911 | 2022/11/30 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东华鲁制药有限公司 | 山东华鲁制药有限公司 | 国药准字H20223865 | 2022/11/22 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广西铭磊维生制药有限公司 | 广西铭磊维生制药有限公司 | 国药准字H20223695 | 2022/09/30 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江花园药业有限公司 | 浙江花园药业有限公司 | 国药准字H20227105 | 2022/08/18 | 20ml:0.2g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 四川美大康华康药业有限公司 | 四川美大康华康药业有限公司 | 国药准字H20223576 | 2022/08/10 | 20ml：0.2g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京百美特生物制药有限公司 | 北京百美特生物制药有限公司 | 国药准字H20223521 | 2022/07/19 | 10ml:0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石药集团欧意药业有限公司 | 石药集团欧意药业有限公司 | 国药准字H20223300 | 2022/05/10 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川美大康华康药业有限公司 | 四川美大康华康药业有限公司 | 国药准字H20213992 | 2021/12/31 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福安药业集团烟台只楚药业有限公司 | 福安药业集团烟台只楚药业有限公司 | 国药准字H20213990 | 2021/12/31 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 安徽恒星制药有限公司 | 安徽恒星制药有限公司 | 国药准字H20217134 | 2021/12/11 | 20ml:0.2g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 广州一品红制药有限公司 | 河北凯威制药有限责任公司 | 国药准字H20213877 | 2021/11/17 | 10ml:0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 云南龙海天然植物药业有限公司 | 云南龙海天然植物药业有限公司 | 国药准字H20213518 | 2021/06/18 | 10ml : 0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 瑞阳制药股份有限公司 | 瑞阳制药股份有限公司 | 国药准字H20183013 | 2021/06/16 | 10ml:0.1g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 福安药业集团宁波天衡制药有限公司 | 福安药业集团宁波天衡制药有限公司 | 国药准字H20041759 | 2021/06/09 | 10ml:0.1g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 维生原（厦门）生物科技有限公司 | 福州海王福药制药有限公司 | 国药准字H20213430/2021S00559 | 2021/06/01 | 10ml：0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 黑龙江福和制药集团股份有限公司 | 黑龙江福和制药集团股份有限公司 | 国药准字H20000304 | 2021/05/25 | 10ml：0.1g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 黑龙江福和制药集团股份有限公司 | 黑龙江福和制药集团股份有限公司 | 国药准字H20083883 | 2021/05/25 | 20ml：0.2g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 山西国润制药有限公司 | 山西国润制药有限公司 | 国药准字H20183135 | 2021/04/29 | 10ml:0.1g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 花园药业股份有限公司 | 花园药业股份有限公司 | 国药准字H20193088 | 2021/01/22 | 10ml:0.1g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 安徽恒星制药有限公司 | 安徽恒星制药有限公司 | 国药准字H20123351 | 2020/12/31 | 10 ml:0.1g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 山西诺成制药有限公司 | 山西诺成制药有限公司 | 国药准字H20183188 | 2020/12/31 | 10ml:0.1g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 浙江北生药业汉生制药有限公司 | 浙江北生药业汉生制药有限公司 | 国药准字H20133217 | 2020/12/24 | 20ml:0.2g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 浙江北生药业汉生制药有限公司 | 浙江北生药业汉生制药有限公司 | 国药准字H20040617 | 2020/12/24 | 10ml:0.1g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 扬子江药业集团南京海陵药业有限公司 | 扬子江药业集团南京海陵药业有限公司 | 国药准字H20203304 | 2020/07/08 | 10ml:0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| — | 石家庄四药有限公司 | 国药准字H20203015 | 2020/01/21 | 10ml:0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 62 distinct approval numbers and 43 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 重庆药友制药有限责任公司 | 国药准字H20183214 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010101066 | NHSA |
| 常州兰陵制药有限公司 | 国药准字H20103810 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010101376 | NHSA |
| 南京臣功制药股份有限公司 | 国药准字H20093474 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010101556 | NHSA |
| 扬子江药业集团南京海陵药业有限公司 | 国药准字H20203304 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010101748 | NHSA |
| 四川益生智同医药生物科技发展有限公司 | 国药准字H20213992 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010102087 | NHSA |
| 陕西博森生物制药股份集团有限公司 | 国药准字H20244561 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010102357 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203015 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010102763 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20223300 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010102770 | NHSA |
| 广州一品红制药有限公司 | 国药准字H20213877 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010102829 | NHSA |
| 通化谷红制药有限公司 | 国药准字H20223911 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010103516 | NHSA |
| 黑龙江福和制药集团股份有限公司 | 国药准字H20000304 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010103731 | NHSA |
| 赤峰万泽药业股份有限公司 | 国药准字H20243638 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010103869 | NHSA |
| 山东鲁抗医药集团赛特有限责任公司 | 国药准字H20243777 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010104131 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20233433 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010104145 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20183013 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010104152 | NHSA |
| 山东益健药业有限公司 | 国药准字H20253302 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010104192 | NHSA |
| 福安药业集团烟台只楚药业有限公司 | 国药准字H20213990 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010104251 | NHSA |
| 国药集团国瑞药业有限公司 | 国药准字H20243015 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010104383 | NHSA |
| 海南卫康制药(潜山)有限公司 | 国药准字H20143049 | 10ml:0.2g | Category B (乙) | XR03DAD179B002010104384 | NHSA |
| 福安药业集团宁波天衡制药有限公司 | 国药准字H20041759 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010104561 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20253360 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010104606 | NHSA |
| 西洲医药科技(浙江)有限公司 | 国药准字H20040617 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010104610 | NHSA |
| 浙江花园药业有限公司 | 国药准字H20193088 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010104646 | NHSA |
| 维生原(厦门)生物科技有限公司 | 国药准字H20213430 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010104827 | NHSA |
| 山西诺成制药有限公司 | 国药准字H20183188 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010105619 | NHSA |
| 浙江海瀚药业有限公司 | 国药准字H20213518 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010106286 | NHSA |
| 四川宏明博思药业有限公司 | 国药准字H20183230 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010106725 | NHSA |
| 安徽恒星制药有限公司 | 国药准字H20123351 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010107478 | NHSA |
| 吉林振澳制药有限公司 | 国药准字H20233215 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010109876 | NHSA |
| ABC Farmaceutici SPA | 国药准字HJ20170323 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010179568 | NHSA |
| 山西国润制药有限公司 | 国药准字H20183135 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010181128 | NHSA |
| 北京百美特生物制药有限公司 | 国药准字H20223521 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010182359 | NHSA |
| 湖北美林药业有限公司 | 国药准字H20244080 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010182474 | NHSA |
| 广西铭磊维生制药有限公司 | 国药准字H20223695 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010182886 | NHSA |
| 河北凯威恒诚制药有限公司 | 国药准字H20243618 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010183007 | NHSA |
| 山东华鲁制药有限公司 | 国药准字H20223865 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010183083 | NHSA |
| 康诺生物制药股份有限公司 | 国药准字H20233192 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010183596 | NHSA |
| 东阳祥昇医药科技有限公司 | 国药准字H20258160 | 20ml:0.2g | Category B (乙) | XR03DAD179B002010184294 | NHSA |
| 云南药科院生物医药股份有限公司 | 国药准字H20255789 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010184308 | NHSA |
| 湖北午时医药研究院有限公司 | 国药准字H20253668 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010184568 | NHSA |
| 开封明仁药业有限公司 | 国药准字H20244712 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010184652 | NHSA |
| 河南普瑞药业有限公司 | 国药准字H20265518 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010184683 | NHSA |
| 重庆药友制药有限责任公司 | 国药准字H20183214 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010201066 | NHSA |
| 常州兰陵制药有限公司 | 国药准字H20103810 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010201376 | NHSA |
| 扬子江药业集团南京海陵药业有限公司 | 国药准字H20203304 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010201748 | NHSA |
| 四川益生智同医药生物科技发展有限公司 | 国药准字H20213992 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010202087 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203015 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010202763 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20223300 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010202770 | NHSA |
| 广州一品红制药有限公司 | 国药准字H20213877 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010202829 | NHSA |
| 通化谷红制药有限公司 | 国药准字H20223911 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010203516 | NHSA |
| 黑龙江福和制药集团股份有限公司 | 国药准字H20000304 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010203731 | NHSA |
| 赤峰万泽药业股份有限公司 | 国药准字H20243638 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010203869 | NHSA |
| 山东鲁抗医药集团赛特有限责任公司 | 国药准字H20243777 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010204131 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20233433 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010204145 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20183013 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010204152 | NHSA |
| 福安药业集团烟台只楚药业有限公司 | 国药准字H20213990 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010204251 | NHSA |
| 国药集团国瑞药业有限公司 | 国药准字H20243015 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010204383 | NHSA |
| 福安药业集团宁波天衡制药有限公司 | 国药准字H20041759 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010204561 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20253360 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010204606 | NHSA |
| 西洲医药科技(浙江)有限公司 | 国药准字H20040617 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010204610 | NHSA |
| 浙江花园药业有限公司 | 国药准字H20193088 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010204646 | NHSA |
| 维生原(厦门)生物科技有限公司 | 国药准字H20213430 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010204827 | NHSA |
| 浙江海瀚药业有限公司 | 国药准字H20213518 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010206286 | NHSA |
| 四川宏明博思药业有限公司 | 国药准字H20183230 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010206725 | NHSA |
| 安徽恒星制药有限公司 | 国药准字H20123351 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010207478 | NHSA |
| 吉林振澳制药有限公司 | 国药准字H20233215 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010209876 | NHSA |
| ABC Farmaceutici SPA | 国药准字HJ20170323 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010279568 | NHSA |
| 山西国润制药有限公司 | 国药准字H20183135 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010281128 | NHSA |
| 北京百美特生物制药有限公司 | 国药准字H20223521 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010282359 | NHSA |
| 湖北美林药业有限公司 | 国药准字H20244080 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010282474 | NHSA |
| 广西铭磊维生制药有限公司 | 国药准字H20223695 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010282886 | NHSA |
| 河北凯威恒诚制药有限公司 | 国药准字H20243618 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010283007 | NHSA |
| 山东华鲁制药有限公司 | 国药准字H20223865 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010283083 | NHSA |
| 康诺生物制药股份有限公司 | 国药准字H20233192 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010283596 | NHSA |
| 云南药科院生物医药股份有限公司 | 国药准字H20255789 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010284308 | NHSA |
| 开封明仁药业有限公司 | 国药准字H20244712 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010284652 | NHSA |
| 河南普瑞药业有限公司 | 国药准字H20265518 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010284683 | NHSA |
| 广州一品红制药有限公司 | 国药准字H20213877 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010302829 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20233433 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010304145 | NHSA |
| 国药集团国瑞药业有限公司 | 国药准字H20243015 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010304383 | NHSA |
| 东阳祥昇医药科技有限公司 | 国药准字H20234452 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010304610 | NHSA |
| 浙江海瀚药业有限公司 | 国药准字H20213518 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010306286 | NHSA |
| 四川宏明博思药业有限公司 | 国药准字H20183230 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010306725 | NHSA |
| 吉林振澳制药有限公司 | 国药准字H20233215 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010309876 | NHSA |
| 湖北美林药业有限公司 | 国药准字H20244080 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010382474 | NHSA |
| 山东华鲁制药有限公司 | 国药准字H20223865 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010383083 | NHSA |
| 石家庄四药有限公司 | 国药准字H20203015 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010402763 | NHSA |
| 广州一品红制药有限公司 | 国药准字H20213877 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010402829 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20233433 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010404145 | NHSA |
| 东阳祥昇医药科技有限公司 | 国药准字H20234452 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010404610 | NHSA |
| 康诺生物制药股份有限公司 | 国药准字H20233192 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010483596 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20233433 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010504145 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20233433 | 10ml:0.1g | Category B (乙) | XR03DAD179B002010604145 | NHSA |
| 重庆药友制药有限责任公司 | 国药准字H20183215 | 10ml:0.2g | Category B (乙) | XR03DAD179B002020101066 | NHSA |
| 扬子江药业集团南京海陵药业有限公司 | 国药准字H20203304 | 10ml:0.1g | Category B (乙) | XR03DAD179B002020101748 | NHSA |
| 四川益生智同医药生物科技发展有限公司 | 国药准字H20223576 | 20ml:0.2g | Category B (乙) | XR03DAD179B002020102087 | NHSA |
| 陕西博森生物制药股份集团有限公司 | 国药准字H20244561 | 10ml:0.1g | Category B (乙) | XR03DAD179B002020102357 | NHSA |
| 通化谷红制药有限公司 | 国药准字H20269032 | 20ml:0.2g | Category B (乙) | XR03DAD179B002020103516 | NHSA |
| 黑龙江福和制药集团股份有限公司 | 国药准字H20083883 | 20ml:0.2g | Category B (乙) | XR03DAD179B002020103731 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20183014 | 10ml:0.2g | Category B (乙) | XR03DAD179B002020104152 | NHSA |
| 海南卫康制药(潜山)有限公司 | 国药准字H20143050 | 20ml:0.3g | Category B (乙) | XR03DAD179B002020104384 | NHSA |
| 福安药业集团宁波天衡制药有限公司 | 国药准字H20174093 | 10ml:0.2g | Category B (乙) | XR03DAD179B002020104561 | NHSA |
| 西洲医药科技(浙江)有限公司 | 国药准字H20133217 | 20ml:0.2g | Category B (乙) | XR03DAD179B002020104610 | NHSA |
| 浙江花园药业有限公司 | 国药准字H20227105 | 20ml:0.2g | Category B (乙) | XR03DAD179B002020104646 | NHSA |
| 山西诺成制药有限公司 | 国药准字H20183188 | 10ml:0.1g | Category B (乙) | XR03DAD179B002020105619 | NHSA |
| 安徽恒星制药有限公司 | 国药准字H20123350 | 20ml:0.3g | Category B (乙) | XR03DAD179B002020107478 | NHSA |
| 山西国润制药有限公司 | 国药准字H20183137 | 10ml:0.2g | Category B (乙) | XR03DAD179B002020181128 | NHSA |
| 湖北美林药业有限公司 | 国药准字H20244081 | 20ml:0.2g | Category B (乙) | XR03DAD179B002020182474 | NHSA |
| 重庆药友制药有限责任公司 | 国药准字H20183215 | 10ml:0.2g | Category B (乙) | XR03DAD179B002020201066 | NHSA |
| 四川益生智同医药生物科技发展有限公司 | 国药准字H20223576 | 20ml:0.2g | Category B (乙) | XR03DAD179B002020202087 | NHSA |
| 黑龙江福和制药集团股份有限公司 | 国药准字H20083883 | 20ml:0.2g | Category B (乙) | XR03DAD179B002020203731 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20183014 | 10ml:0.2g | Category B (乙) | XR03DAD179B002020204152 | NHSA |
| 福安药业集团宁波天衡制药有限公司 | 国药准字H20174093 | 10ml:0.2g | Category B (乙) | XR03DAD179B002020204561 | NHSA |
| 浙江花园药业有限公司 | 国药准字H20227105 | 20ml:0.2g | Category B (乙) | XR03DAD179B002020204646 | NHSA |
| 安徽恒星制药有限公司 | 国药准字H20123350 | 20ml:0.3g | Category B (乙) | XR03DAD179B002020207478 | NHSA |
| 山西国润制药有限公司 | 国药准字H20183137 | 10ml:0.2g | Category B (乙) | XR03DAD179B002020281128 | NHSA |
| 湖北美林药业有限公司 | 国药准字H20244081 | 20ml:0.2g | Category B (乙) | XR03DAD179B002020282474 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20183014 | 10ml:0.2g | Category B (乙) | XR03DAD179B002020304152 | NHSA |
| 陕西博森生物制药股份集团有限公司 | 国药准字H20244562 | 20ml:0.2g | Category B (乙) | XR03DAD179B002030102357 | NHSA |
| 黑龙江福和制药集团股份有限公司 | 国药准字H20083758 | 20ml:0.3g | Category B (乙) | XR03DAD179B002030103731 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20183015 | 20ml:0.3g | Category B (乙) | XR03DAD179B002030104152 | NHSA |
| 浙江北生药业汉生制药有限公司 | 国药准字H20113407 | 20ml:0.3g | Category B (乙) | XR03DAD179B002030104610 | NHSA |
| 安徽恒星制药有限公司 | 国药准字H20143182 | 10ml:0.2g | Category B (乙) | XR03DAD179B002030107478 | NHSA |
| 山西国润制药有限公司 | 国药准字H20183136 | 20ml:0.3g | Category B (乙) | XR03DAD179B002030181128 | NHSA |
| 陕西博森生物制药股份集团有限公司 | 国药准字H20244562 | 20ml:0.2g | Category B (乙) | XR03DAD179B002030202357 | NHSA |
| 黑龙江福和制药集团股份有限公司 | 国药准字H20083758 | 20ml:0.3g | Category B (乙) | XR03DAD179B002030203731 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20183015 | 20ml:0.3g | Category B (乙) | XR03DAD179B002030204152 | NHSA |
| 安徽恒星制药有限公司 | 国药准字H20143182 | 10ml:0.2g | Category B (乙) | XR03DAD179B002030207478 | NHSA |
| 山西国润制药有限公司 | 国药准字H20183136 | 20ml:0.3g | Category B (乙) | XR03DAD179B002030281128 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20183015 | 20ml:0.3g | Category B (乙) | XR03DAD179B002030304152 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20183015 | 20ml:0.3g | Category B (乙) | XR03DAD179B002030404152 | NHSA |
| 浙江北生药业汉生制药有限公司 | 国药准字H20113407 | 20ml:0.3g | Category B (乙) | XR03DAD179B002040104610 | NHSA |
| 安徽恒星制药有限公司 | 国药准字H20217134 | 20ml:0.2g | Category B (乙) | XR03DAD179B002040107478 | NHSA |
| 西洲医药科技(浙江)有限公司 | 国药准字H20133217 | 20ml:0.2g | Category B (乙) | XR03DAD179B002040204610 | NHSA |
| 西洲医药科技(浙江)有限公司 | 国药准字H20133217 | 20ml:0.2g | Category B (乙) | XR03DAD179B002040304610 | NHSA |
| 安徽恒星制药有限公司 | 国药准字H20217134 | 20ml:0.2g | Category B (乙) | XR03DAD179B002050107478 | NHSA |
| 通化谷红制药有限公司 | 国药准字H20269032 | 20ml:0.2g | Category B (乙) | XR03DAD179B002020203516 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 5 filings and 5 distinct first applicants.
Generic 4 · Supplement 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 湖北津药药业股份有限公司 | CYHS2602174 | Generic | 2026/09/01 | Not stated by source | CDE |
| 信合援生制药股份有限公司 | CYHS2601660 | Generic | 2026/07/13 | Not stated by source | CDE |
| 安徽双鹤药业有限责任公司 | CYHS2504015 | Generic | 2025/11/20 | Not stated by source | CDE |
| 格林菲尔德（江苏）药业有限公司;悦康药业集团股份有限公司 | CYHS2201234 | Generic | 2022/08/04 | Not stated by source | CDE |
| 广西铭磊维生制药有限公司 | CYHB2601943 | Supplement | 2026/10/23 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 2 filings and 2 distinct first applicants.
API registrations
Non-component matches: 23 companies with A status and 4 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 多索茶碱 | 四川伊诺达博医药科技有限公司 | Y20250000769 | I | Exact ingredient | 2025/08/19 | CDE |
| 多索茶碱 | 白云山东泰商丘药业有限公司 | Y20250000283 | I | Exact ingredient | 2025/04/30 | CDE |
| 多索茶碱 | 湖北午时药业股份有限公司 | Y20230001361 | A | Exact ingredient | 2026/09/10 | CDE |
| 多索茶碱 | 浙江赛默制药有限公司 | Y20230000425 | A | Exact ingredient | 2026/07/03 | CDE |
| 多索茶碱 | 河南省联谊制药有限公司 | Y20230000052 | A | Exact ingredient | 2025/07/05 | CDE |
| 多索茶碱 | 浙江永宁药业股份有限公司 | Y20220000979 | A | Exact ingredient | 2024/07/30 | CDE |
| 多索茶碱 | 成都百裕制药股份有限公司 | Y20210001237 | A | Exact ingredient | 2025/12/31 | CDE |
| 多索茶碱 | 国药集团国瑞药业有限公司 | Y20210001212 | A | Exact ingredient | 2024/01/20 | CDE |
| 多索茶碱 | 河北广祥制药有限公司 | Y20210000927 | A | Exact ingredient | 2026/07/25 | CDE |
| 多索茶碱 | 赤峰万泽药业股份有限公司 | Y20210001004 | A | Exact ingredient | 2025/05/15 | CDE |
| 多索茶碱 | 湖北美林药业有限公司 | Y20210000516 | A | Exact ingredient | 2023/04/18 | CDE |
| 多索茶碱 | 山东鲁抗医药股份有限公司 | Y20210000238 | A | Exact ingredient | 2023/09/07 | CDE |
| 多索茶碱 | 陕西博森生物制药股份集团有限公司 | Y20200000718 | A | Exact ingredient | 2023/03/24 | CDE |
| 多索茶碱 | 扬子江药业集团江苏海慈生物药业有限公司 | Y20200000750 | A | Exact ingredient | 2026/10/31 | CDE |
| 多索茶碱 | 山东方明药业集团股份有限公司 | Y20200000471 | A | Exact ingredient | 2025/11/01 | CDE |
| 多索茶碱 | 石药创新制药股份有限公司 | Y20190001151 | A | Exact ingredient | 2024/01/17 | CDE |
| 多索茶碱 | Delta Finochem Private Limited | Y20190001108 | I | Exact ingredient | 2019/11/10 | CDE |
| 多索茶碱 | 福安药业集团宁波天衡制药有限公司 | Y20190009492 | A | Exact ingredient | 2025/05/15 | CDE |
| 多索茶碱 | 黑龙江福和制药集团股份有限公司 | Y20190008493 | A | Exact ingredient | 2026/04/29 | CDE |
| 多索茶碱 | 浙江昂利康制药股份有限公司 | Y20190007315 | A | Exact ingredient | 2023/10/08 | CDE |
| 多索茶碱 | 浙江昌明药业有限公司 | Y20190001752 | A | Exact ingredient | 2025/05/30 | CDE |
| 多索茶碱 | Cohance Lifesciences Limited | Y20190000458 | A | Exact ingredient | 2026/01/17 | CDE |
| 多索茶碱 | 福安药业集团宁波天衡制药有限公司 | Y20190000170 | I | Exact ingredient | 2019/03/26 | CDE |
| 多索茶碱 | Ami Lifesciences Pvt. Ltd. | Y20170001857 | A | Exact ingredient | 2023/07/28 | CDE |
| 多索茶碱 | 浙江北生药业汉生制药有限公司 | Y20170001388 | A | Exact ingredient | 2025/11/22 | CDE |
| 多索茶碱 | 安徽恒星制药有限公司 | Y20170001273 | A | Exact ingredient | 2023/12/13 | CDE |
| 多索茶碱 | 辽宁药联制药有限公司 | Y20170000856 | A | Exact ingredient | 2024/01/10 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/10/23Accepted
-
2026/09/01Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Doxofylline Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy